Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

Upon binding to the receptors, cascades of tyrosine and serine kinases are stimulated to facilitate growth or metabolism. The IGF2 receptor is a scavenger receptor, and is, therefore, not involved ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

to ErbB receptors activates a sequence of canonical intracellular pathways downstream from many receptor tyrosine kinases (RTKs), such as phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of ...